Last reviewed · How we verify
NCT05916222: DTTC
The Effects of Caregiver Training on DTTC Treatment Outcomes in CAS
NA trial testing Dynamic Temporal and Tactile Cueing (DTTC) in Childhood Apraxia of Speech in 40 participants. Currently enrolling.
30 May 2026
Quick facts
| Lead sponsor | New York University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 19 July 2023 |
| Primary completion | 30 May 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Dynamic Temporal and Tactile Cueing (DTTC)
Conditions studied
- Childhood Apraxia of Speech — all drugs for Childhood Apraxia of Speech →
Sponsor
New York University
Who can join
Adults 24 Months to 95 Months, any sex, with Childhood Apraxia of Speech. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to investigate the impact of direct vs. indirect caregiver training on treatment outcomes following a period of Dynamic Temporal and Tactile Cueing (DTTC) intervention combined with home practice in childhood apraxia of speech (CAS). Forty children with CAS, between the ages of 2;5 and 7;11 years of age, will be recruited for this study. All children will receive DTTC treatment at the frequency of standard care (2x/week) in a university clinic over and 8-week period. Participants will be randomly assigned to one of two groups: the Direct Training Group; the Indirect Training Group. All caregivers will complete an educational module about CAS, will observe all sessions, and will engage in home practice with their children. Caregivers in the Direct Group will receive coaching in the use of DTTC with their child during a portion of each treatment session to support home practice, whereas those in the Indirect Group will not receive detailed guidance for home practice. Caregivers in both groups will practice at home with their children during the treatment phase (3x/week). Following the treatment phase, home practice will continue at a higher frequency (6x/week) during a 4-week follow-up phase. Treatment outcomes will be compared between groups.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05916222
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Childhood Apraxia of Speech
Currently open trials in the same condition.
- NCT06385470 — Treatment of Cantonese Speakers With Childhood Apraxia of Speech · NA · recruiting
- NCT05675306 — Dose Frequency RCT on DTTC in Children With CAS · NA · active not recruiting
- NCT04642053 — A Randomized Control Trial of Motor-based Intervention for CAS · NA · recruiting
- NCT03903120 — ASSIST: Treatment for Childhood Apraxia of Speech · Phase 1 · active not recruiting
Other New York University trials
Trials by the same sponsor.
- NCT07526246 — Motor-based Intervention for Childhood Apraxia of Speech: DTTC-Connect · NA · not yet recruiting
- NCT07519941 — Promoting Change in Practice for Respiratory Failure · NA · not yet recruiting
- NCT07071753 — Optimizing Online Purchasing of Fruits, Vegetables, and Legumes for Low-Income Families · NA · not yet recruiting
- NCT07530900 — Prediction of Visual Feedback Effects on Speech Motor Adaptation in Healthy Adults · NA · not yet recruiting
- NCT07278934 — Testing the Impact of Family-Based Intervention to Improve Developmental and Health Outcomes for Female Adolescents · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05916222 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York University
- Last refreshed: 20 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05916222.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing